Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?

Author： Luke Jason John   Ott Patrick Alexander  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.18, 2013-12, pp. : 2457-2462

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety

By  

Current Cancer Drug Targets, Vol. 15, Iss. 6, 2015-01 ,pp. : 452-462

Bentham Science Publishers

Access to resources Recommend Favorite

Current Inhibitors of Checkpoint Kinase 2

By  

Current Medicinal Chemistry, Vol. 18, Iss. 28, 2011-10 ,pp. : 4368-4374

Bentham Science Publishers

Access to resources Recommend Favorite

Complete Estrogen Blockade for the Treatment of Metastatic and Early Stage Breast Cancer

By Michaud L.B.   Buzdar A.U.  

Drugs & Aging, Vol. 16, Iss. 4, 2000-04 ,pp. : 261-271

Adis International

Access to resources Recommend Favorite

Protein kinase inhibitors in melanoma

By Eigentler Thomas K   Meier Friedegund   Garbe Claus  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2195-2201

Informa Healthcare

Access to resources Recommend Favorite

Metabolism considerations for kinase inhibitors in cancer treatment

By Duckett Derek R   Cameron Michael D  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, Iss. 10, 2010-10 ,pp. : 1175-1193

Informa Healthcare

Access to resources Recommend Favorite